parallel randomized trial
NCT03842202
Effect of Semaglutide 2.4 mg Once-weekly on Gastric Emptying in Subjects With Obesity
Design
Conduct and analysis
Arms
| Arm | Treatment | Background | Randomized | Analyzed | Completed treatment |
|---|---|---|---|---|---|
| A1 | Semaglutide 2.4 mg subcutaneous once weekly Semaglutide 2.4 mg | none; lifestyle: none | 36 | ||
| A2 | Placebo Placebo | none; lifestyle: none | 36 |
Baseline characteristics
As printed in the trial reports or registry, per arm or for the whole trial.
| Characteristic | Statistic | Semaglutide 2.4 mg subcutaneous once weekly A1 | Placebo A2 |
|---|---|---|---|
| age | mean (years) | 40.7 | 45.0 |
| age | sd (years) | 12.2 | 9.5 |
| black | n | 1 | 0 |
| black | percent | 2.8 | 0.0 |
| bmi | mean (kg/m2) | 34.2 | 34.6 |
| bmi | sd (kg/m2) | 3.0 | 3.1 |
| female | n | 12 | 16 |
| female | percent | 33.3 | 44.4 |
| hispanic | n | 0 | 0 |
| weight | mean (kg) | 106.2 | 104.9 |
| weight | sd (kg) | 16.2 | 14.0 |
| white | n | 35 | 36 |
| white | percent | 97.2 | 100.0 |
Analyses this trial contributes to
- Serious adverse eventsOverweight or obesity without diabetes (adults); longest follow-up; network meta-analysis
- Serious adverse eventsOverweight or obesity without diabetes (adults); longest follow-up; network meta-analysis
- NauseaOverweight or obesity without diabetes (adults); longest follow-up; network meta-analysis
- NauseaOverweight or obesity without diabetes (adults); longest follow-up; network meta-analysis
- VomitingOverweight or obesity without diabetes (adults); longest follow-up; network meta-analysis
- VomitingOverweight or obesity without diabetes (adults); longest follow-up; network meta-analysis
- DiarrheaOverweight or obesity without diabetes (adults); longest follow-up; network meta-analysis
- DiarrheaOverweight or obesity without diabetes (adults); longest follow-up; network meta-analysis
Results
12 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Percent body weight change (2 lines; O10)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 20 | A1 | percent change | -9.9 percent | not stated; other; R0023297:Results | |||
| 20 | A2 | percent change | -0.4 percent | not stated; other; R0023297:Results |
Serious adverse events (2 lines; O25)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 1 / 36 | not stated; safety; R0023297:Supplement Table S3 | ||||
| A2 | events | 1 / 36 | not stated; safety; R0023297:Supplement Table S3 |
Discontinuation due to adverse events (2 lines; O26)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 36 | not stated; safety; R0023297:Supplement Table S3 | ||||
| A2 | events | 1 / 36 | not stated; safety; R0023297:Supplement Table S3 |
Nausea (2 lines; O27A)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 17 / 36 | not stated; safety; R0023297:Supplement Table S3 | ||||
| A2 | events | 6 / 36 | not stated; safety; R0023297:Supplement Table S3 |
Vomiting (2 lines; O27B)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 8 / 36 | not stated; safety; R0023297:Supplement Table S3 | ||||
| A2 | events | 1 / 36 | not stated; safety; R0023297:Supplement Table S3 |
Diarrhea (2 lines; O27C)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 16 / 36 | not stated; safety; R0023297:Supplement Table S3 | ||||
| A2 | events | 4 / 36 | not stated; safety; R0023297:Supplement Table S3 |